Journal
CYTOMETRY PART A
Volume 97, Issue 7, Pages 662-667Publisher
WILEY
DOI: 10.1002/cyto.a.24047
Keywords
coronavirus; 2019-nCoV; SARS-CoV-2; COVID-19; antibody-dependent enhancement
Categories
Funding
- Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)
- Fundacao de Amparo a Pesquisa do Estado do Rio Grande do Sul (FAPERGS)
- Fundacao de Amparo a Pesquisa do Estado de Sao Paulo [FAPESP, 2018/08426-0]
Ask authors/readers for more resources
SARS-CoV-2 pandemic and recurrent dengue epidemics in tropical countries have turned into a global health threat. While both virus-caused infections may only reveal light symptoms, they can also cause severe diseases. Here, we review the possible antibody-dependent enhancement (ADE) occurrence, known for dengue infections, when there is a second infection with a different virus strain. Consequently, preexisting antibodies do not neutralize infection, but enhance it, possibly by triggering Fc gamma receptor-mediated virus uptake. No clinical data exist indicating such mechanism for SARS-CoV-2, but previous coronavirus infections or infection of SARS-CoV-2 convalescent with different SARS-CoV-2 strains could promote ADE, as experimentally shown for antibodies against the MERS-CoV or SARS-CoV spike S protein. (c) 2020 International Society for Advancement of Cytometry
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available